



Belgian Cancer Registry

CANCER FACT SHEET 2023

COLORECTAL CANCER

ICD-10 C18-C20



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. For colorectal cancer, stage IV means the cancer has spread to other organs. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

- **Clinical stage:** Stage based on clinical examinations (e.g.: medical imaging, biopsies) to estimate the extent of the tumour. Clinical stage is established before the start of any treatment.
- **Pathological stage:** Stage based on pathological examinations of the tumour after surgery. **Pathological stage without neo-adjuvant therapy** is the pathological stage in the population that did not receive neo-adjuvant therapy prior to surgery. **Pathological stage after neo-adjuvant therapy** is the pathological stage in the population that did receive neo-adjuvant therapy prior to surgery. Pathological stage regardless of neo-adjuvant therapy is reported as (y)pStage.
- **Neo-adjuvant therapy (NAT):** Treatment (e.g.: chemotherapy/radiotherapy) given prior to surgery, with the goal to shrink the tumour before operating.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Colorectal cancer incidence: by region	5
1.1.1. Colorectal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023.....	5
1.2. Colorectal cancer incidence: by tumour stage	7
1.2.1. Colorectal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	7
1.2.2. Colorectal cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	7
1.2.3. Colorectal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	8
1.2.4. Colorectal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	9
1.2.5. Rectal cancer incidence by stage variables, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	10
2. CANCER INCIDENCE TRENDS	11
2.1. Colorectal cancer incidence trends: by region.....	11
2.1.1. Colorectal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	11
2.1.2. Colorectal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	13
2.2. Colorectal cancer incidence trends: by tumour stage	14
2.2.1. Colorectal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards...	14
2.3. Colorectal cancer incidence trends: by age group.....	16
2.3.1. Colorectal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	16
2.3.2. Colorectal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	17
3. CANCER PREVALENCE	18
3.1. Colorectal cancer prevalence: by region.....	18
3.1.1. Colorectal cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023.....	18
4. CANCER SURVIVAL.....	19
4.1. Colorectal cancer survival: by region	19
4.1.1. Colorectal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023.....	19
4.2. Colorectal cancer survival: by sub-location and tumour stage	21
4.2.1. Colorectal cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023	21
4.2.2. Colorectal cancer survival by sub-location, pathological stage ((y)pStage) and sex: number at risk and net survival probabilities, 2014-2023.....	23

4.2.3. Colorectal cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2014-2023	25
5. CANCER SURVIVAL TRENDS.....	27
5.1. Colorectal cancer survival trends: by tumour stage.....	27
5.1.1. Colorectal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023	27
5.2. Colorectal cancer survival trends: by sub-location and tumour stage.....	29
5.2.1. Colorectal cancer survival trends by sub-location, stage and sex: number at risk and net survival probabilities, 2004-2023	29
6. CANCER MORTALITY	32
6.1. Colorectal cancer mortality: by region.....	32
6.1.1. Colorectal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	32
7. CANCER MORTALITY TRENDS.....	34
7.1. Colorectal cancer mortality trends: by region	34
7.1.1. Colorectal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	34
7.1.2. Colorectal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	36

1. CANCER INCIDENCE



1.1. Colorectal cancer incidence: by region

1.1.1. Colorectal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	2	3	7	7	11	27	38	54	108	234	319	491	625	719	633	501	381	120	15	4,295	79.3
	[0.0]	[0.6]	[0.8]	[2.1]	[2.0]	[3.0]	[6.9]	[10.1]	[14.0]	[28.9]	[59.2]	[79.3]	[131.0]	[196.5]	[269.9]	[311.4]	[401.2]	[477.9]	[383.0]	[247.5]	[74.5]	(77.0; 81.7)
Brussels	0	0	2	2	0	4	6	3	4	17	24	36	34	38	53	39	36	16	11	0	325	81.0
	[0.0]	[0.0]	[5.1]	[5.4]	[0.0]	[7.8]	[11.3]	[6.4]	[8.7]	[38.6]	[58.6]	[101.7]	[117.9]	[177.9]	[315.1]	[308.9]	[447.5]	[319.8]	[477.6]	[0.0]	[53.4]	(71.9; 90.1)
Flanders	0	1	1	4	6	4	14	19	29	64	122	175	255	330	398	360	308	268	74	13	2,445	72.4
	[0.0]	[0.5]	[0.5]	[2.1]	[3.2]	[2.0]	[6.5]	[9.0]	[13.1]	[30.3]	[53.2]	[72.2]	[111.4]	[168.4]	[242.5]	[276.2]	[373.6]	[498.2]	[355.7]	[327.5]	[72.9]	(69.5; 75.3)
Wallonia	0	1	0	1	1	3	7	16	21	27	88	108	202	257	268	234	157	97	35	2	1,525	92.7
	[0.0]	[1.0]	[0.0]	[0.9]	[0.9]	[2.7]	[5.8]	[13.7]	[18.0]	[22.8]	[70.2]	[86.6]	[172.7]	[254.9]	[313.8]	[388.0]	[456.4]	[463.5]	[425.5]	[128.7]	[84.7]	(88.0; 97.4)
Females																						
Belgium	0	1	2	5	4	13	47	39	71	106	177	221	320	420	532	558	444	370	174	38	3,542	54.8
	[0.0]	[0.3]	[0.6]	[1.5]	[1.2]	[3.6]	[12.0]	[10.3]	[18.5]	[28.8]	[45.6]	[55.7]	[83.8]	[124.0]	[179.1]	[227.1]	[254.9]	[276.5]	[245.5]	[182.5]	[59.7]	(53.0; 56.6)
Brussels	0	0	0	0	1	3	1	4	6	9	18	25	28	31	53	42	25	15	16	2	279	55.4
	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[5.4]	[1.8]	[8.3]	[13.1]	[21.9]	[47.0]	[73.4]	[92.6]	[124.0]	[247.1]	[233.3]	[194.6]	[153.0]	[282.1]	[96.1]	[44.1]	(48.8; 61.9)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	2	3	2	6	27	25	48	61	97	125	174	242	275	323	273	251	110	19	2,063	52.6
	[0.0]	[0.0]	[1.0]	[1.7]	[1.1]	[3.0]	[12.5]	[11.7]	[21.7]	[29.3]	[43.2]	[52.9]	[76.2]	[119.7]	[156.6]	[215.0]	[249.5]	[294.1]	[250.0]	[155.1]	[60.3]	(50.3; 54.9)
Wallonia	0	1	0	2	1	4	19	10	17	36	62	71	118	147	204	193	146	104	48	17	1,200	58.9
	[0.0]	[1.0]	[0.0]	[1.8]	[0.9]	[3.7]	[15.9]	[8.5]	[14.4]	[30.4]	[49.4]	[56.1]	[95.9]	[131.9]	[203.9]	[249.2]	[281.2]	[268.9]	[226.5]	[262.2]	[63.8]	(55.5; 62.2)

1.2. Colorectal cancer incidence: by tumour stage

1.2.1. Colorectal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

cStage	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-49	50-74	75+	All ages		15-49	50-74	75+	All ages	
I	44 [1.7]	524 [29.8]	317 [71.2]	885 [15.4]	16.2 (15.2; 17.3)	55 [2.2]	328 [18.2]	284 [44.0]	668 [11.3]	10.5 (9.7; 11.3)
II	32 [1.2]	371 [21.1]	363 [81.5]	766 [13.3]	14.4 (13.4; 15.4)	34 [1.3]	253 [14.0]	348 [53.9]	635 [10.7]	9.5 (8.7; 10.2)
III	65 [2.5]	567 [32.3]	327 [73.4]	959 [16.6]	17.5 (16.4; 18.7)	63 [2.5]	397 [22.0]	356 [55.2]	816 [13.7]	12.7 (11.8; 13.5)
IV	56 [2.2]	468 [26.6]	313 [70.3]	837 [14.5]	15.4 (14.4; 16.5)	58 [2.3]	338 [18.7]	286 [44.3]	682 [11.5]	10.7 (9.8; 11.5)
X/NA	55 [2.1]	458 [26.1]	330 [74.1]	848 [14.7]	15.7 (14.7; 16.8)	75 [2.9]	354 [19.6]	310 [48.0]	741 [12.5]	11.5 (10.7; 12.3)

1.2.2. Colorectal cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

(y)pStage	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-49	50-74	75+	All ages		15-49	50-74	75+	All ages	
I	59 [2.3]	714 [40.6]	369 [82.9]	1,146 [19.9]	20.9 (19.6; 22.1)	83 [3.3]	435 [24.1]	316 [49.0]	836 [14.1]	13.3 (12.4; 14.2)
II	62 [2.4]	470 [26.8]	435 [97.7]	968 [16.8]	18.1 (16.9; 19.2)	56 [2.2]	394 [21.9]	440 [68.2]	891 [15.0]	13.6 (12.7; 14.5)
III	76 [3.0]	579 [33.0]	339 [76.1]	994 [17.3]	18.2 (17.1; 19.4)	66 [2.6]	401 [22.2]	362 [56.1]	829 [14.0]	12.8 (11.9; 13.7)
IV	21 [0.8]	160 [9.1]	80 [18.0]	261 [4.5]	4.8 (4.2; 5.3)	34 [1.3]	122 [6.8]	74 [11.5]	230 [3.9]	3.7 (3.2; 4.2)
X/NA	34 [1.3]	465 [26.5]	427 [95.9]	926 [16.1]	17.4 (16.3; 18.6)	46 [1.8]	318 [17.6]	392 [60.7]	756 [12.7]	11.4 (10.6; 12.2)

1.2.3. Colorectal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-74	75+	All ages		15-49	50-74	75+	All ages	
I	55 [2.1]	679 [38.6]	391 [87.8]	1,129 [19.6]	20.6 (19.4; 21.8)	81 [3.2]	428 [23.7]	328 [50.8]	839 [14.1]	13.2 (12.3; 14.2)
II	53 [2.1]	462 [26.3]	469 [105.3]	985 [17.1]	18.5 (17.3; 19.7)	54 [2.1]	384 [21.3]	489 [75.8]	928 [15.6]	14.0 (13.1; 15.0)
III	87 [3.4]	707 [40.2]	403 [90.5]	1,197 [20.8]	22.0 (20.7; 23.2)	85 [3.3]	456 [25.3]	406 [62.9]	947 [16.0]	14.7 (13.7; 15.6)
IV	57 [2.2]	497 [28.3]	334 [75.0]	888 [15.4]	16.4 (15.3; 17.5)	64 [2.5]	361 [20.0]	305 [47.3]	730 [12.3]	11.4 (10.6; 12.2)
X/NA	0 [0.0]	43 [2.4]	53 [11.9]	96 [1.7]	1.9 (1.5; 2.2)	1 [0.0]	41 [2.3]	56 [8.7]	98 [1.7]	1.4 (1.1; 1.7)

1.2.4. Colorectal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Sub-locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-74	75+	All ages		15-49	50-74	75+	All ages	
Colon	I	36 [1.4]	473 [26.9]	277 [62.2]	790 [13.7]	14.5 (13.5; 15.5)	53 [2.1]	303 [16.8]	269 [41.7]	627 [10.6]	9.8 (9.1; 10.6)
	II	44 [1.7]	350 [19.9]	381 [85.6]	776 [13.5]	14.6 (13.6; 15.6)	46 [1.8]	323 [17.9]	424 [65.7]	794 [13.4]	12.0 (11.1; 12.8)
	III	47 [1.8]	399 [22.7]	260 [58.4]	706 [12.3]	13.0 (12.1; 14.0)	43 [1.7]	301 [16.7]	310 [48.0]	654 [11.0]	10.0 (9.3; 10.8)
	IV	46 [1.8]	369 [21.0]	256 [57.5]	671 [11.6]	12.4 (11.4; 13.3)	46 [1.8]	274 [15.2]	253 [39.2]	573 [9.7]	8.9 (8.2; 9.6)
	X/NA	0 [0.0]	26 [1.5]	35 [7.9]	61 [1.1]	1.2 (0.9; 1.5)	1 [0.0]	26 [1.4]	47 [7.3]	74 [1.2]	1.1 (0.8; 1.3)
Rectum	I	19 [0.7]	206 [11.7]	114 [25.6]	339 [5.9]	6.2 (5.5; 6.8)	28 [1.1]	125 [6.9]	59 [9.1]	212 [3.6]	3.4 (2.9; 3.9)
	II	9 [0.4]	112 [6.4]	88 [19.8]	209 [3.6]	3.9 (3.4; 4.4)	8 [0.3]	61 [3.4]	65 [10.1]	134 [2.3]	2.1 (1.7; 2.4)
	III	40 [1.6]	308 [17.5]	143 [32.1]	491 [8.5]	8.9 (8.1; 9.7)	42 [1.7]	155 [8.6]	96 [14.9]	293 [4.9]	4.7 (4.1; 5.2)
	IV	11 [0.4]	128 [7.3]	78 [17.5]	217 [3.8]	4.0 (3.5; 4.5)	18 [0.7]	87 [4.8]	52 [8.1]	157 [2.6]	2.5 (2.1; 2.9)
	X/NA	0 [0.0]	17 [1.0]	18 [4.0]	35 [0.6]	0.7 (0.5; 0.9)	0 [0.0]	15 [0.8]	9 [1.4]	24 [0.4]	0.4 (0.2; 0.5)

1.2.5. Rectal cancer incidence by stage variables, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage variables	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-74	75+	All ages		15-49	50-74	75+	All ages	
Clinical stage	I	17 [0.7]	167 [9.5]	90 [20.2]	274 [4.8]	5.0 (4.4; 5.6)	22 [0.9]	89 [4.9]	50 [7.7]	161 [2.7]	2.6 (2.2; 3.0)
	II	11 [0.4]	98 [5.6]	91 [20.4]	200 [3.5]	3.8 (3.2; 4.3)	10 [0.4]	56 [3.1]	63 [9.8]	129 [2.2]	2.0 (1.6; 2.3)
	III	35 [1.4]	302 [17.2]	140 [31.4]	477 [8.3]	8.6 (7.9; 9.4)	39 [1.5]	163 [9.0]	100 [15.5]	302 [5.1]	4.8 (4.3; 5.3)
	IV	11 [0.4]	126 [7.2]	77 [17.3]	214 [3.7]	3.9 (3.4; 4.5)	17 [0.7]	84 [4.7]	50 [7.7]	151 [2.5]	2.4 (2.0; 2.8)
	X/NA	5 [0.2]	78 [4.4]	43 [9.7]	126 [2.2]	2.3 (1.9; 2.7)	8 [0.3]	51 [2.8]	18 [2.8]	77 [1.3]	1.2 (0.9; 1.5)
Pathological stage without NAT	I	17 [0.7]	188 [10.7]	90 [20.2]	295 [5.1]	5.3 (4.7; 6.0)	23 [0.9]	109 [6.0]	46 [7.1]	178 [3.0]	2.9 (2.5; 3.3)
	II	5 [0.2]	53 [3.0]	43 [9.7]	101 [1.8]	1.9 (1.5; 2.2)	4 [0.2]	26 [1.4]	25 [3.9]	55 [0.9]	0.8 (0.6; 1.1)
	III	13 [0.5]	75 [4.3]	35 [7.9]	123 [2.1]	2.3 (1.9; 2.7)	11 [0.4]	28 [1.6]	21 [3.3]	60 [1.0]	0.9 (0.7; 1.2)
	IV	1 [0.0]	13 [0.7]	5 [1.1]	19 [0.3]	0.3 (0.2; 0.5)	3 [0.1]	10 [0.6]	5 [0.8]	18 [0.3]	0.3 (0.2; 0.4)
	X/NA	16 [0.6]	217 [12.4]	190 [42.7]	423 [7.3]	7.9 (7.2; 8.7)	25 [1.0]	149 [8.3]	135 [20.9]	309 [5.2]	4.7 (4.2; 5.3)
Pathological stage after NAT	I	7 [0.3]	61 [3.5]	16 [3.6]	84 [1.5]	1.5 (1.2; 1.8)	8 [0.3]	26 [1.4]	12 [1.9]	46 [0.8]	0.7 (0.5; 1.0)
	II	8 [0.3]	54 [3.1]	22 [4.9]	84 [1.5]	1.5 (1.2; 1.8)	6 [0.2]	29 [1.6]	9 [1.4]	44 [0.7]	0.7 (0.5; 0.9)
	III	8 [0.3]	59 [3.4]	23 [5.2]	90 [1.6]	1.6 (1.3; 2.0)	8 [0.3]	39 [2.2]	14 [2.2]	61 [1.0]	1.0 (0.7; 1.2)
	IV	1 [0.0]	9 [0.5]	2 [0.4]	12 [0.2]	0.2 (0.1; 0.3)	4 [0.2]	5 [0.3]	3 [0.5]	12 [0.2]	0.2 (0.1; 0.3)
	X/NA	3 [0.1]	42 [2.4]	15 [3.4]	60 [1.0]	1.1 (0.8; 1.3)	4 [0.2]	22 [1.2]	11 [1.7]	37 [0.6]	0.6 (0.4; 0.8)

2. CANCER INCIDENCE TRENDS



2.1. Colorectal cancer incidence trends: by region

2.1.1. Colorectal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium N	4,108	4,155	4,261	4,250	4,518	4,538	4,592	4,802	4,753	4,804	5,609	4,933	4,769	4,591	4,319	4,330	3,984	4,392	4,264	4,295		
CR	80.8	81.3	82.8	82.0	86.5	86.1	86.4	89.4	87.8	88.2	102.5	89.6	86.1	82.5	77.2	76.9	70.4	77.4	74.7	74.5		
ESR2013	106.1	105.0	106.6	103.1	107.7	106.3	104.7	108.6	105.9	104.9	120.4	103.8	99.1	92.8	86.3	84.7	77.1	84.1	80.3	79.3	-1.6 (-2.0; -1.1)	2004-2023
																					0.7 (-0.3; 1.7)	2004-2013
																					-4.5 (-6.5; -2.4)	2014-2017
																					-2.9 (-4.6; -1.2)	2018-2023
Brussels N	299	316	310	337	339	281	357	355	321	314	320	302	338	337	324	303	267	325	324	325		
CR	62.2	65.3	63.3	67.8	67.1	54.4	67.8	65.5	58.1	55.9	56.5	52.7	58.3	57.9	55.2	51.1	44.7	54.3	54.0	53.4		
ESR2013	94.5	96.5	95.2	102.8	102.5	84.1	103.4	103.4	93.3	88.9	90.0	84.4	92.3	92.4	87.0	81.3	70.6	83.6	84.7	81.0	-1.2 (-1.8; -0.6)	2004-2023
Flanders N	2,603	2,642	2,748	2,699	2,933	2,983	2,906	3,082	3,060	3,063	3,929	3,288	2,970	2,773	2,568	2,560	2,457	2,598	2,485	2,445		
CR	87.7	88.7	91.7	89.5	96.5	97.4	94.2	99.0	97.6	97.2	124.1	103.3	92.8	86.1	79.2	78.5	74.9	78.9	74.9	72.9		
ESR2013	110.8	110.2	112.5	106.9	113.9	113.6	107.8	113.6	110.1	107.9	136.1	111.3	98.9	90.3	82.5	80.2	76.2	79.8	74.9	72.4	-2.2 (-2.9; -1.5)	2004-2023
																					1.0 (-0.5; 2.5)	2004-2013
																					-6.2 (-9.1; -3.3)	2014-2017
																					-4.1 (-6.4; -1.6)	2018-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Wallonia N	1,206	1,197	1,203	1,214	1,246	1,274	1,329	1,365	1,372	1,427	1,360	1,343	1,461	1,481	1,427	1,467	1,260	1,469	1,455	1,525		
CR	73.5	72.6	72.6	72.8	74.3	75.5	78.2	79.6	79.5	82.3	78.1	76.8	83.2	83.9	80.6	82.6	70.7	82.3	81.2	84.7		
ESR2013	100.0	97.2	97.8	95.5	96.5	96.8	98.9	99.9	100.3	102.8	95.3	93.4	100.8	98.2	93.6	94.8	80.6	92.5	90.0	92.7	-0.5 (-0.9; -0.1)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Colorectal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium N	3,505	3,466	3,584	3,645	3,717	3,733	3,743	3,760	3,896	3,894	4,132	3,854	3,770	3,649	3,589	3,711	3,349	3,478	3,435	3,542		
CR	66.0	65.0	66.8	67.5	68.3	68.1	67.7	67.4	69.3	68.9	72.8	67.6	65.8	63.4	62.1	63.9	57.4	59.5	58.5	59.7		
ESR2013	66.2	65.0	66.2	66.0	66.8	65.9	65.4	65.0	66.5	66.0	70.5	63.9	62.2	59.3	57.2	58.8	52.6	54.5	53.2	54.8	-1.3 (-1.5; -1.0)	2004-2023
																					0.0 (-0.5; 0.5)	2004-2014
																					-2.7 (-3.2; -2.1)	2015-2023
Brussels N	327	327	351	294	304	278	321	342	300	299	300	306	306	291	286	319	274	266	268	279		
CR	62.9	62.5	66.3	55.0	56.1	50.3	57.0	59.3	51.2	50.4	50.3	50.8	50.3	47.8	46.7	51.8	44.2	42.8	43.1	44.1		
ESR2013	65.1	64.5	70.9	58.6	60.3	54.9	62.7	67.5	58.2	58.8	59.2	60.6	61.1	56.8	55.4	61.9	53.0	51.2	51.6	55.4	-1.0 (-1.5; -0.5)	2004-2023
Flanders N	2,050	2,005	2,143	2,215	2,298	2,334	2,344	2,226	2,399	2,413	2,698	2,377	2,302	2,191	2,135	2,194	2,010	2,081	1,984	2,063		
CR	67.2	65.5	69.6	71.4	73.6	74.2	74.0	69.7	74.6	74.7	83.1	72.9	70.2	66.5	64.5	65.9	60.0	61.9	58.7	60.3		
ESR2013	67.0	64.9	68.1	68.8	70.7	70.2	69.7	65.3	69.1	68.7	77.7	66.1	63.3	59.4	55.9	57.7	52.1	53.5	50.6	52.6	-1.7 (-2.0; -1.3)	2004-2023
																					0.4 (-0.4; 1.1)	2004-2014
																					-3.9 (-4.7; -3.0)	2015-2023
Wallonia N	1,128	1,134	1,090	1,136	1,115	1,121	1,078	1,192	1,197	1,182	1,134	1,171	1,162	1,167	1,168	1,198	1,065	1,131	1,183	1,200		
CR	64.8	64.9	62.0	64.2	62.7	62.7	59.9	65.8	65.7	64.6	61.8	63.6	63.0	63.1	63.0	64.5	57.2	60.7	63.2	63.8		
ESR2013	65.3	65.2	61.0	63.1	61.2	61.1	58.2	63.6	63.7	62.7	59.7	60.8	60.2	59.8	59.6	60.2	53.2	56.9	58.3	58.9	-0.6 (-0.9; -0.3)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Colorectal cancer incidence trends: by tumour stage

2.2.1. Colorectal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage		Males							Females						
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
I	N	1,074	920	1,041	1,017	1,129			824	745	764	758	839		
	CR	19.1	16.3	18.3	17.8	19.6			14.2	12.8	13.1	12.9	14.1		
	ESR2013	20.8	17.6	19.8	19.0	20.6	1.2 (0.1; 2.3)	2004-2023	13.3	11.9	12.1	11.9	13.2	2.2 (1.4; 2.9)	2004-2023
							4.2 (2.6; 6.0)	2004-2017						5.3 (4.2; 6.5)	2004-2015
							-5.2 (-8.9; -1.4)	2018-2023						-3.6 (-6.6; -0.6)	2016-2019
														-0.4 (-4.3; 3.6)	2020-2023
II	N	1,032	948	1,057	999	985			968	888	920	914	928		
	CR	18.3	16.7	18.6	17.5	17.1			16.7	15.2	15.7	15.6	15.6		
	ESR2013	20.4	18.6	20.4	19.1	18.5	-2.3 (-2.7; -2.0)	2004-2023	15.0	13.7	14.1	13.9	14.0	-1.5 (-1.9; -1.2)	2004-2023
							-0.3 (-1.1; 0.5)	2004-2013						-0.3 (-1.0; 0.5)	2004-2013
							-5.4 (-7.0; -3.9)	2014-2017						-4.6 (-6.1; -3.0)	2014-2017
							-3.2 (-4.5; -1.9)	2018-2023						-1.4 (-2.7; -0.2)	2018-2023
III	N	1,200	1,118	1,225	1,160	1,197			1,002	921	986	972	947		
	CR	21.3	19.8	21.6	20.3	20.8			17.3	15.8	16.9	16.5	16.0		
	ESR2013	23.4	21.5	23.2	21.5	22.0	-1.1 (-1.7; -0.6)	2004-2023	16.0	14.6	15.5	15.1	14.7	-1.1 (-1.4; -0.8)	2004-2023
							3.1 (1.4; 4.7)	2004-2011						1.0 (0.3; 1.8)	2004-2013
							-2.8 (-5.1; -0.4)	2012-2015						-3.0 (-3.6; -2.4)	2014-2023
							-3.9 (-5.2; -2.6)	2016-2023							
IV	N	908	889	969	974	888			806	713	724	689	730		
	CR	16.1	15.7	17.1	17.1	15.4			13.9	12.2	12.4	11.7	12.3		

Stage	Males							Females						
	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
ESR2013	17.7	17.2	18.6	18.3	16.4	-0.1 (-0.5; 0.3)	2004-2023	12.9	11.3	11.5	10.8	11.4	0.7 (0.3; 1.1)	2004-2023
						1.7 (0.6; 2.7)	2004-2012						2.7 (1.4; 4.1)	2004-2011
						-1.4 (-2.1; -0.7)	2013-2023						-0.5 (-1.2; 0.2)	2012-2023
X/NA N CR ESR2013	116	109	100	114	96			111	82	84	102	98		
	2.1	1.9	1.8	2.0	1.7			1.9	1.4	1.4	1.7	1.7		
	2.4	2.2	2.0	2.3	1.9	-12.2 (-13.1; -11.2)	2004-2023	1.6	1.2	1.2	1.5	1.4	-11.3 (-12.5; -10.0)	2004-2023
						-9.2 (-11.7; -6.6)	2004-2012						-9.3 (-11.7; -6.9)	2004-2014
						-14.9 (-19.1; -10.6)	2013-2016						-18.0 (-23.1; -12.7)	2015-2018
						-13.9 (-16.6; -11.0)	2017-2023						-9.5 (-15.1; -3.7)	2019-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Colorectal cancer incidence trends: by age group

2.3.1. Colorectal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-39 N	43	55	61	61	49	72	70	66	65	88	56	65	65	85	69	82	72	102	82	90		
CR	2.5	3.2	3.5	3.5	2.8	4.1	4.0	3.8	3.7	5.0	3.2	3.7	3.7	4.8	3.9	4.6	4.0	5.7	4.6	5.0		
ESR2013	2.4	3.2	3.5	3.6	2.9	4.2	4.1	3.9	3.8	5.1	3.3	3.8	3.8	4.9	4.0	4.7	4.2	5.8	4.7	5.1	2.7 (1.5; 3.9)	2004-2023
40-49 N	194	160	179	176	200	147	175	169	176	187	189	159	171	164	130	173	160	166	173	162		
CR	24.6	20.0	22.2	21.6	24.5	18.0	21.5	20.7	21.6	23.1	23.6	20.1	22.0	21.3	17.0	22.7	21.1	21.9	22.9	21.4		
ESR2013	24.8	20.1	22.3	21.8	24.6	18.0	21.4	20.5	21.4	22.8	23.4	20.0	21.7	21.1	16.8	22.5	20.9	21.9	22.9	21.5	-0.2 (-1.0; 0.5)	2004-2023
50-74 N	2,358	2,391	2,367	2,328	2,491	2,564	2,556	2,684	2,611	2,602	3,521	2,825	2,709	2,618	2,452	2,434	2,158	2,432	2,330	2,388		
CR	174.9	175.1	171.3	166.3	175.4	177.5	174.0	179.4	171.6	168.4	224.3	176.9	166.7	158.2	145.9	143.2	125.6	140.1	133.5	135.9		
ESR2013	182.6	182.8	180.6	176.3	187.0	190.5	186.0	192.3	185.0	182.4	243.9	187.7	179.3	166.0	152.3	148.0	129.2	143.0	135.9	138.2	-1.6 (-2.4; -0.8)	2004-2023
																					1.5 (-0.3; 3.2)	2004-2013
																					-4.8 (-8.2; -1.4)	2014-2017
																					-3.9 (-6.6; -1.1)	2018-2023
75+ N	1,509	1,545	1,651	1,682	1,777	1,752	1,786	1,881	1,898	1,923	1,838	1,882	1,815	1,717	1,666	1,639	1,592	1,684	1,673	1,650		
CR	514.8	510.4	525.7	516.3	527.7	507.0	504.5	520.7	514.2	511.3	479.3	480.7	459.8	434.9	419.4	405.6	385.0	404.7	388.0	370.5		
ESR2013	522.1	514.7	534.9	510.6	524.7	503.3	495.4	520.3	513.6	502.8	475.7	482.6	455.0	427.0	411.2	395.8	379.1	401.8	386.1	369.0	-1.9 (-2.1; -1.7)	2004-2023
																					-0.3 (-0.9; 0.3)	2004-2012
																					-3.0 (-3.4; -2.6)	2013-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Colorectal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-39 N	49	56	67	68	79	66	73	71	90	92	79	89	92	91	92	89	85	94	86	108		
CR	2.9	3.3	4.0	4.0	4.7	3.9	4.3	4.1	5.2	5.3	4.6	5.1	5.3	5.2	5.3	5.1	4.8	5.4	4.9	6.0		
ESR2013	2.9	3.3	4.0	4.0	4.7	3.9	4.3	4.2	5.3	5.5	4.7	5.2	5.4	5.3	5.3	5.1	4.9	5.4	4.9	6.0	2.9 (2.1; 3.6)	2004-2023
																					6.2 (3.8; 8.6)	2004-2011
																					1.0 (-0.2; 2.2)	2012-2023
40-49 N	126	162	170	169	143	152	149	153	169	153	154	158	157	135	127	133	134	153	162	177		
CR	16.2	20.6	21.4	21.2	17.9	19.1	18.7	19.2	21.3	19.4	19.7	20.5	20.7	18.0	17.0	17.8	18.0	20.5	21.7	23.5		
ESR2013	16.3	20.7	21.6	21.3	17.9	19.0	18.6	19.0	21.2	19.3	19.6	20.4	20.6	17.7	16.8	17.7	17.9	20.5	21.8	23.6	1.1 (0.3; 1.8)	2004-2023
																					0.8 (-0.7; 2.2)	2004-2014
																					-4.5 (-7.7; -1.1)	2015-2018
																					6.4 (2.8; 10.0)	2019-2023
50-74 N	1,632	1,627	1,641	1,583	1,686	1,655	1,684	1,666	1,725	1,770	2,066	1,789	1,755	1,752	1,637	1,730	1,532	1,645	1,510	1,670		
CR	113.3	111.9	111.9	106.9	112.7	109.2	109.4	106.5	108.6	109.9	126.7	108.1	104.4	102.5	94.5	98.8	86.7	92.3	84.3	92.6		
ESR2013	112.3	111.4	112.6	108.6	115.2	111.6	112.7	110.3	112.4	114.0	132.1	111.4	108.4	104.7	95.7	99.5	86.8	91.9	83.8	92.0	-1.5 (-1.9; -1.1)	2004-2023
																					0.2 (-0.6; 1.0)	2004-2015
																					-3.8 (-4.9; -2.7)	2016-2023
75+ N	1,697	1,616	1,703	1,819	1,804	1,856	1,828	1,864	1,910	1,874	1,826	1,815	1,763	1,670	1,729	1,754	1,590	1,582	1,672	1,584		
CR	326.4	304.3	312.8	326.3	316.7	320.9	311.6	314.2	318.3	310.1	299.2	294.1	286.0	272.7	282.9	285.6	256.2	255.6	263.8	245.4		
ESR2013	325.7	306.9	311.8	323.1	313.0	316.5	305.5	309.6	312.9	303.6	294.5	288.2	278.6	264.0	271.0	275.8	249.0	247.5	259.4	243.7	-1.4 (-1.6; -1.2)	2004-2023
																					-0.3 (-0.9; 0.4)	2004-2011
																					-2.0 (-2.4; -1.7)	2012-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Colorectal cancer prevalence: by region

3.1.1. Colorectal cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	N	3,742	14,636	25,831	32,807	36,884	3,105	12,292	21,504	27,682	31,685
	CR	64.5	252.5	445.6	566	636	52.0	206.0	360.4	464	531
	ESR2013	67.7	266.2	472.7	604.2	682.0	47.8	186.3	323.2	412.8	469.9
Brussels	N	287	1,016	1,675	2,102	2,361	251	946	1,600	2,052	2,342
	CR	46.9	166.0	273.6	343.4	385.7	39.4	148.4	251.0	321.9	367.4
	ESR2013	69.9	254.3	429.0	545.4	619.4	49.3	181.2	304.5	389.0	442.4
Flanders	N	2,155	8,759	16,355	21,016	23,791	1,827	7,398	13,394	17,340	19,878
	CR	63.8	259.3	484.2	622.2	704.4	53.0	214.8	388.9	503.4	577.1
	ESR2013	62.6	254.8	476.7	615.0	697.8	46.4	184.3	330.9	424.5	483.3
Wallonia	N	1,300	4,861	7,801	9,689	10,732	1,027	3,948	6,510	8,290	9,465
	CR	71.9	268.9	431.6	536.0	593.7	54.5	209.5	345.4	439.8	502.2
	ESR2013	77.0	291.6	472.1	591.2	659.1	50.0	190.8	312.5	395.6	450.0

4. CANCER SURVIVAL



4.1. Colorectal cancer survival: by region

4.1.1. Colorectal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	79,318	86.2% (85.9%; 86.4%)	75.8% (75.4%; 76.2%)	71.3% (70.7%; 71.8%)	66.9% (65.2%; 68.6%)
Males						
Belgium	All ages	43,884	86.8% (86.4%; 87.1%)	76.2% (75.6%; 76.7%)	70.8% (70.1%; 71.5%)	66.0% (63.7%; 68.4%)
	15-49	2,350	95.0% (94.2%; 95.9%)	83.0% (81.4%; 84.6%)	76.4% (74.5%; 78.3%)	70.4% (68.0%; 73.0%)
	50-74	25,108	90.8% (90.4%; 91.1%)	80.5% (80.0%; 81.1%)	74.7% (74.0%; 75.4%)	70.3% (69.2%; 71.4%)
	75+	16,468	79.5% (78.7%; 80.2%)	68.5% (67.5%; 69.6%)	64.1% (62.6%; 65.6%)	58.6% (52.6%; 65.2%)
Brussels	All ages	3,036	83.5% (82.0%; 85.0%)	70.7% (68.7%; 72.8%)	65.2% (62.6%; 67.9%)	58.0% (50.0%; 67.2%)
	15-49	281	92.3% (89.2%; 95.5%)	77.8% (72.8%; 83.1%)	67.2% (61.2%; 73.9%)	58.3% (49.9%; 68.0%)
	50-74	1,683	86.8% (85.1%; 88.5%)	75.5% (73.2%; 77.9%)	68.1% (65.4%; 70.9%)	60.7% (56.5%; 65.2%)
	75+	1,074	76.0% (73.0%; 79.1%)	61.3% (57.2%; 65.7%)	59.8% (54.3%; 66.0%)	51.6% (34.7%; 76.9%)
Flanders	All ages	27,102	88.4% (88.0%; 88.9%)	79.3% (78.7%; 80.0%)	75.1% (74.2%; 76.0%)	71.8% (68.7%; 75.1%)
	15-49	1,297	96.3% (95.3%; 97.4%)	84.8% (82.8%; 86.9%)	78.7% (76.2%; 81.2%)	73.5% (70.4%; 76.7%)
	50-74	15,158	92.5% (92.1%; 93.0%)	84.3% (83.6%; 85.0%)	79.6% (78.7%; 80.5%)	77.8% (76.4%; 79.2%)
	75+	10,673	81.6% (80.7%; 82.6%)	71.6% (70.2%; 73.0%)	68.3% (66.4%; 70.2%)	62.7% (54.9%; 71.7%)
Wallonia	All ages	13,747	84.1% (83.5%; 84.8%)	71.1% (70.2%; 72.1%)	63.4% (62.2%; 64.6%)	55.1% (52.2%; 58.2%)

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-49	772	93.9% (92.2%; 95.6%)	81.9% (79.1%; 84.7%)	75.6% (72.3%; 79.0%)	69.1% (64.7%; 73.8%)
	50-74	8,268	88.3% (87.5%; 89.0%)	74.6% (73.5%; 75.6%)	66.9% (65.7%; 68.2%)	56.5% (54.6%; 58.6%)
	75+	4,721	75.4% (73.9%; 76.8%)	63.3% (61.3%; 65.3%)	55.2% (52.6%; 58.0%)	50.0% (42.8%; 58.4%)
Females						
Belgium	All ages	35,434	85.4% (85.0%; 85.8%)	75.4% (74.8%; 76.0%)	71.8% (71.0%; 72.6%)	68.1% (65.7%; 70.5%)
	15-49	2,361	94.7% (93.8%; 95.6%)	84.9% (83.4%; 86.4%)	79.7% (77.9%; 81.5%)	76.4% (74.3%; 78.5%)
	50-74	16,657	90.9% (90.5%; 91.4%)	80.8% (80.1%; 81.4%)	76.1% (75.3%; 76.9%)	72.5% (71.3%; 73.7%)
	75+	16,449	78.5% (77.7%; 79.2%)	68.6% (67.6%; 69.7%)	66.3% (64.9%; 67.7%)	62.4% (57.4%; 67.9%)
Brussels	All ages	2,785	82.8% (81.3%; 84.4%)	72.7% (70.6%; 74.8%)	68.3% (65.5%; 71.2%)	67.8% (55.1%; 83.4%)
	15-49	254	94.5% (91.7%; 97.4%)	81.7% (76.8%; 86.8%)	78.5% (73.3%; 84.2%)	73.0% (66.0%; 80.8%)
	50-74	1,291	89.8% (88.1%; 91.5%)	78.2% (75.7%; 80.7%)	70.5% (67.6%; 73.5%)	64.6% (60.5%; 69.0%)
	75+	1,240	73.2% (70.5%; 76.1%)	65.0% (61.4%; 69.0%)	63.7% (58.5%; 69.4%)	69.1% (47.5%; 100.6%)
Flanders	All ages	21,371	87.1% (86.6%; 87.7%)	78.2% (77.4%; 78.9%)	75.7% (74.7%; 76.6%)	73.4% (70.8%; 76.0%)
	15-49	1,394	95.2% (94.1%; 96.4%)	86.3% (84.5%; 88.2%)	81.3% (79.1%; 83.6%)	78.8% (76.3%; 81.5%)
	50-74	9,816	92.5% (92.0%; 93.1%)	83.6% (82.8%; 84.4%)	80.3% (79.3%; 81.3%)	78.4% (76.9%; 79.9%)
	75+	10,182	80.8% (79.9%; 81.7%)	71.9% (70.5%; 73.2%)	70.5% (68.7%; 72.3%)	67.9% (62.5%; 73.8%)
Wallonia	All ages	11,278	82.7% (82.0%; 83.5%)	70.8% (69.8%; 71.9%)	65.2% (63.9%; 66.6%)	57.5% (53.2%; 62.2%)
	15-49	713	93.8% (92.0%; 95.6%)	83.1% (80.3%; 86.0%)	76.9% (73.5%; 80.3%)	72.7% (68.8%; 76.8%)
	50-74	5,550	88.3% (87.5%; 89.2%)	76.3% (75.1%; 77.5%)	69.8% (68.4%; 71.2%)	63.1% (61.0%; 65.2%)
	75+	5,027	75.0% (73.7%; 76.4%)	63.0% (61.2%; 64.9%)	58.5% (56.0%; 61.0%)	49.4% (41.2%; 59.3%)

4.2. Colorectal cancer survival: by sub-location and tumour stage

4.2.1. Colorectal cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023

location	cStage	Net Survival Probability, 2014-2023						
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total		79,318	86.2% (85.9%; 86.4%)	79.9% (79.6%; 80.3%)	75.8% (75.4%; 76.2%)	73.0% (72.5%; 73.4%)	71.3% (70.7%; 71.8%)	66.9% (65.2%; 68.6%)
Males								
CRC	All	43,884	86.8% (86.4%; 87.1%)	80.5% (80.0%; 80.9%)	76.2% (75.6%; 76.7%)	72.9% (72.3%; 73.5%)	70.8% (70.1%; 71.5%)	66.0% (63.7%; 68.4%)
	I	7,010	96.1% (95.5%; 96.8%)	95.0% (94.1%; 95.9%)	93.8% (92.7%; 94.9%)	92.4% (91.0%; 93.8%)	91.8% (90.1%; 93.5%)	94.2% (89.3%; 99.4%)
	II	6,333	92.0% (91.2%; 92.9%)	88.6% (87.5%; 89.8%)	85.1% (83.7%; 86.5%)	82.2% (80.5%; 83.9%)	80.1% (78.0%; 82.1%)	65.5% (53.1%; 80.8%)
	III	9,021	93.8% (93.1%; 94.4%)	89.3% (88.4%; 90.2%)	85.8% (84.7%; 86.9%)	82.4% (81.2%; 83.7%)	80.3% (78.8%; 81.8%)	76.4% (72.8%; 80.2%)
	IV	8,236	61.9% (60.8%; 63.1%)	42.3% (41.2%; 43.5%)	29.9% (28.8%; 31.0%)	22.3% (21.2%; 23.4%)	17.9% (16.8%; 19.0%)	10.6% (9.2%; 12.3%)
	X/NA	14,007	89.7% (89.1%; 90.3%)	86.2% (85.5%; 87.0%)	83.9% (83.1%; 84.8%)	81.8% (80.8%; 82.8%)	80.3% (79.1%; 81.5%)	76.4% (73.5%; 79.4%)
Colon	All	30,495	86.0% (85.5%; 86.4%)	79.8% (79.2%; 80.4%)	75.8% (75.2%; 76.5%)	72.7% (72.0%; 73.5%)	70.9% (70.0%; 71.7%)	66.0% (62.9%; 69.2%)
	I	4,564	96.4% (95.6%; 97.2%)	95.5% (94.4%; 96.6%)	94.4% (93.0%; 95.8%)	92.8% (91.0%; 94.6%)	91.8% (89.6%; 94.0%)	89.9% (83.6%; 96.7%)
	II	4,404	92.8% (91.8%; 93.8%)	90.0% (88.6%; 91.3%)	86.8% (85.1%; 88.5%)	85.0% (82.9%; 87.0%)	82.8% (80.3%; 85.4%)	66.3% (48.7%; 90.2%)
	III	4,099	92.2% (91.2%; 93.3%)	87.5% (86.1%; 88.9%)	84.0% (82.3%; 85.7%)	80.9% (78.9%; 82.9%)	79.2% (76.9%; 81.6%)	80.7% (74.4%; 87.5%)
	IV	5,831	59.2% (57.9%; 60.6%)	39.6% (38.3%; 41.0%)	28.1% (26.8%; 29.4%)	20.8% (19.6%; 22.1%)	16.7% (15.5%; 18.0%)	9.6% (7.9%; 11.8%)
	X/NA	11,961	90.4% (89.8%; 91.1%)	87.0% (86.2%; 87.8%)	84.9% (83.9%; 85.8%)	82.6% (81.5%; 83.8%)	81.3% (80.0%; 82.7%)	77.4% (74.1%; 80.7%)
Rectum	All	13,963	88.4% (87.7%; 89.0%)	81.8% (81.0%; 82.6%)	76.7% (75.8%; 77.6%)	72.8% (71.7%; 73.9%)	70.3% (69.2%; 71.5%)	66.0% (63.5%; 68.6%)
	I	2,480	95.5% (94.3%; 96.6%)	93.8% (92.3%; 95.3%)	92.4% (90.5%; 94.3%)	91.2% (89.0%; 93.5%)	91.2% (88.5%; 94.0%)	100.4% (93.1%; 108.3%)
	II	1,948	90.4% (88.8%; 92.1%)	85.6% (83.5%; 87.7%)	81.4% (78.9%; 83.9%)	76.2% (73.2%; 79.3%)	74.2% (70.9%; 77.6%)	63.2% (55.7%; 71.8%)
	III	4,962	95.0% (94.2%; 95.8%)	90.7% (89.6%; 91.8%)	87.2% (85.8%; 88.6%)	83.6% (82.0%; 85.3%)	81.2% (79.3%; 83.1%)	73.9% (69.6%; 78.4%)
	IV	2,442	68.4% (66.5%; 70.4%)	48.7% (46.6%; 50.9%)	34.2% (32.2%; 36.4%)	25.8% (23.8%; 27.9%)	20.7% (18.8%; 22.8%)	12.8% (10.7%; 15.4%)
	X/NA	2,140	85.7% (84.0%; 87.4%)	81.5% (79.5%; 83.6%)	78.5% (76.2%; 80.8%)	76.9% (74.3%; 79.6%)	74.4% (71.4%; 77.5%)	72.0% (66.4%; 78.0%)

Net Survival Probability, 2014-2023									
location	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Females									
CRC	All	35,434	85.4% (85.0%; 85.8%)	79.2% (78.7%; 79.8%)	75.4% (74.8%; 76.0%)	73.1% (72.4%; 73.8%)	71.8% (71.0%; 72.6%)	68.1% (65.7%; 70.5%)	
	I	5,174	97.0% (96.3%; 97.7%)	96.2% (95.2%; 97.1%)	95.5% (94.3%; 96.7%)	94.9% (93.4%; 96.5%)	94.0% (92.1%; 95.9%)	86.3% (76.1%; 97.8%)	
	II	5,315	90.9% (89.9%; 91.8%)	87.8% (86.6%; 89.0%)	84.4% (82.9%; 86.0%)	82.1% (80.3%; 83.9%)	80.6% (78.4%; 82.8%)	76.6% (69.0%; 85.0%)	
	III	7,150	91.6% (90.8%; 92.4%)	87.5% (86.5%; 88.5%)	84.4% (83.2%; 85.6%)	82.3% (80.9%; 83.7%)	82.5% (81.0%; 84.2%)	85.2% (80.2%; 90.5%)	
	IV	6,267	57.4% (56.2%; 58.7%)	37.9% (36.6%; 39.2%)	27.2% (26.0%; 28.4%)	21.3% (20.2%; 22.5%)	18.0% (16.9%; 19.2%)	13.4% (11.9%; 15.1%)	
	X/NA	12,020	88.9% (88.3%; 89.6%)	84.8% (83.9%; 85.6%)	82.4% (81.5%; 83.4%)	81.0% (79.9%; 82.1%)	79.8% (78.5%; 81.1%)	75.3% (71.9%; 78.9%)	
<i>Colon</i>	All	27,105	84.8% (84.3%; 85.3%)	78.7% (78.1%; 79.3%)	75.2% (74.5%; 75.9%)	73.2% (72.4%; 74.0%)	72.1% (71.2%; 73.0%)	68.5% (65.5%; 71.5%)	
	I	3,725	96.7% (95.8%; 97.5%)	96.1% (94.9%; 97.2%)	95.6% (94.2%; 97.1%)	95.4% (93.6%; 97.3%)	94.6% (92.4%; 97.0%)	90.5% (77.0%; 106.4%)	
	II	4,137	91.1% (90.0%; 92.2%)	88.6% (87.2%; 90.0%)	85.7% (83.9%; 87.4%)	83.7% (81.6%; 85.7%)	82.2% (79.6%; 84.8%)	79.3% (69.7%; 90.2%)	
	III	4,031	90.2% (89.1%; 91.3%)	86.6% (85.2%; 88.0%)	83.7% (82.1%; 85.5%)	82.5% (80.6%; 84.6%)	84.2% (81.9%; 86.5%)	89.1% (80.2%; 99.0%)	
	IV	4,906	56.1% (54.7%; 57.6%)	36.2% (34.8%; 37.6%)	25.8% (24.5%; 27.2%)	20.4% (19.2%; 21.8%)	17.5% (16.3%; 18.9%)	13.9% (12.2%; 15.9%)	
	X/NA	10,623	89.4% (88.7%; 90.1%)	85.4% (84.6%; 86.3%)	83.4% (82.4%; 84.4%)	82.1% (80.9%; 83.3%)	80.9% (79.6%; 82.3%)	75.9% (72.2%; 79.9%)	
<i>Rectum</i>	All	8,600	87.3% (86.5%; 88.1%)	80.7% (79.7%; 81.7%)	75.9% (74.8%; 77.1%)	72.5% (71.3%; 73.8%)	70.5% (69.1%; 71.9%)	66.4% (63.4%; 69.5%)	
	I	1,460	97.8% (96.7%; 99.0%)	96.6% (95.0%; 98.3%)	95.0% (92.9%; 97.2%)	93.8% (91.2%; 96.5%)	92.4% (89.2%; 95.7%)	77.1% (66.9%; 88.8%)	
	II	1,188	90.0% (88.0%; 92.1%)	85.1% (82.4%; 87.8%)	80.2% (77.0%; 83.5%)	77.0% (73.3%; 80.8%)	75.2% (71.1%; 79.6%)	67.9% (58.9%; 78.2%)	
	III	3,133	93.4% (92.3%; 94.4%)	88.6% (87.2%; 90.0%)	85.1% (83.5%; 86.8%)	81.9% (80.0%; 83.9%)	80.6% (78.4%; 82.8%)	81.4% (76.7%; 86.5%)	
	IV	1,373	62.2% (59.6%; 64.9%)	44.0% (41.3%; 46.8%)	32.1% (29.5%; 35.0%)	24.6% (22.1%; 27.3%)	19.8% (17.4%; 22.5%)	12.3% (9.6%; 15.8%)	
	X/NA	1,449	85.2% (83.1%; 87.3%)	79.1% (76.6%; 81.7%)	74.6% (71.8%; 77.6%)	72.5% (69.3%; 75.7%)	70.4% (67.0%; 74.0%)	68.9% (63.1%; 75.2%)	

4.2.2. Colorectal cancer survival by sub-location, pathological stage ((y)pStage) and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023									
location	(y)pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total		79,318	86.2% (85.9%; 86.4%)	79.9% (79.6%; 80.3%)	75.8% (75.4%; 76.2%)	73.0% (72.5%; 73.4%)	71.3% (70.7%; 71.8%)	66.9% (65.2%; 68.6%)	
Males									
CRC	All	43,884	86.8% (86.4%; 87.1%)	80.5% (80.0%; 80.9%)	76.2% (75.6%; 76.7%)	72.9% (72.3%; 73.5%)	70.8% (70.1%; 71.5%)	66.0% (63.7%; 68.4%)	
	I	11,665	98.2% (97.8%; 98.7%)	98.0% (97.4%; 98.6%)	97.9% (97.1%; 98.6%)	97.2% (96.3%; 98.2%)	97.1% (96.0%; 98.3%)	97.7% (94.6%; 100.9%)	
	II	10,770	95.4% (94.8%; 96.0%)	93.7% (92.9%; 94.5%)	92.1% (91.1%; 93.1%)	89.9% (88.7%; 91.1%)	88.7% (87.2%; 90.2%)	78.8% (71.2%; 87.2%)	
	III	10,796	90.6% (90.0%; 91.3%)	83.3% (82.4%; 84.2%)	77.1% (76.1%; 78.2%)	72.1% (70.9%; 73.4%)	68.4% (67.0%; 69.8%)	63.4% (60.2%; 66.8%)	
	IV	2,856	73.3% (71.6%; 75.1%)	54.4% (52.4%; 56.4%)	41.9% (39.9%; 44.0%)	33.6% (31.6%; 35.8%)	27.6% (25.6%; 29.7%)	15.7% (12.7%; 19.3%)	
	X/NA	8,634	60.1% (59.0%; 61.2%)	45.3% (44.2%; 46.5%)	36.7% (35.5%; 37.9%)	32.0% (30.7%; 33.3%)	29.6% (28.3%; 31.0%)	25.6% (23.6%; 27.9%)	
Colon	All	30,495	86.0% (85.5%; 86.4%)	79.8% (79.2%; 80.4%)	75.8% (75.2%; 76.5%)	72.7% (72.0%; 73.5%)	70.9% (70.0%; 71.7%)	66.0% (62.9%; 69.2%)	
	I	7,592	97.9% (97.4%; 98.5%)	97.9% (97.1%; 98.7%)	97.5% (96.6%; 98.5%)	96.9% (95.7%; 98.1%)	96.8% (95.3%; 98.3%)	95.6% (91.8%; 99.5%)	
	II	8,602	95.1% (94.5%; 95.8%)	93.6% (92.8%; 94.5%)	92.4% (91.3%; 93.5%)	90.8% (89.4%; 92.2%)	90.0% (88.3%; 91.7%)	80.6% (71.3%; 91.1%)	
	III	8,173	89.4% (88.6%; 90.2%)	81.8% (80.8%; 82.9%)	75.9% (74.6%; 77.1%)	71.4% (70.0%; 72.9%)	67.8% (66.2%; 69.5%)	64.3% (60.4%; 68.6%)	
	IV	2,352	71.1% (69.2%; 73.1%)	52.1% (49.9%; 54.3%)	39.8% (37.6%; 42.1%)	31.6% (29.4%; 33.9%)	26.1% (24.0%; 28.5%)	16.0% (12.6%; 20.3%)	
	X/NA	4,282	48.2% (46.7%; 49.8%)	31.4% (29.9%; 33.0%)	23.5% (22.0%; 25.0%)	18.5% (17.0%; 20.0%)	16.5% (15.1%; 18.1%)	13.0% (11.0%; 15.4%)	
Rectum	All	13,963	88.4% (87.7%; 89.0%)	81.8% (81.0%; 82.6%)	76.7% (75.8%; 77.6%)	72.8% (71.7%; 73.9%)	70.3% (69.2%; 71.5%)	66.0% (63.5%; 68.6%)	
	I	4,167	98.8% (98.2%; 99.5%)	98.1% (97.1%; 99.0%)	98.4% (97.2%; 99.6%)	97.8% (96.3%; 99.2%)	97.6% (95.8%; 99.5%)	101.5% (96.2%; 107.1%)	
	II	2,195	96.5% (95.4%; 97.7%)	94.0% (92.5%; 95.6%)	91.0% (89.0%; 93.1%)	86.6% (84.2%; 89.1%)	83.9% (81.1%; 86.9%)	72.6% (65.4%; 80.5%)	
	III	2,660	94.2% (93.1%; 95.4%)	87.8% (86.2%; 89.4%)	81.1% (79.1%; 83.1%)	74.3% (72.0%; 76.8%)	69.9% (67.2%; 72.6%)	60.6% (55.9%; 65.7%)	
	IV	522	83.4% (80.0%; 86.9%)	65.0% (60.7%; 69.6%)	50.8% (46.2%; 55.8%)	42.4% (37.8%; 47.6%)	34.0% (29.4%; 39.3%)	15.5% (10.5%; 22.7%)	
	X/NA	4,427	71.5% (70.1%; 73.0%)	58.7% (57.1%; 60.4%)	49.3% (47.6%; 51.1%)	44.8% (43.0%; 46.8%)	42.2% (40.1%; 44.3%)	38.1% (34.6%; 41.9%)	
Females									
CRC	All	35,434	85.4% (85.0%; 85.8%)	79.2% (78.7%; 79.8%)	75.4% (74.8%; 76.0%)	73.1% (72.4%; 73.8%)	71.8% (71.0%; 72.6%)	68.1% (65.7%; 70.5%)	

Net Survival Probability, 2014-2023									
location	(y)pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	I	8,303	99.1% (98.6%; 99.5%)	98.9% (98.3%; 99.5%)	98.6% (97.8%; 99.5%)	98.7% (97.6%; 99.7%)	98.4% (97.1%; 99.7%)	101.2% (97.4%; 105.2%)	
	II	9,414	95.7% (95.1%; 96.3%)	95.0% (94.2%; 95.8%)	94.0% (93.0%; 95.0%)	92.9% (91.7%; 94.2%)	92.4% (90.9%; 94.0%)	83.9% (78.9%; 89.3%)	
	III	8,998	89.1% (88.3%; 89.8%)	81.5% (80.5%; 82.5%)	76.1% (74.9%; 77.2%)	72.6% (71.3%; 73.9%)	70.7% (69.2%; 72.2%)	65.0% (58.9%; 71.7%)	
	IV	2,660	69.5% (67.7%; 71.4%)	51.0% (49.0%; 53.0%)	39.8% (37.8%; 41.9%)	32.6% (30.6%; 34.7%)	28.1% (26.1%; 30.2%)	20.1% (17.8%; 22.8%)	
	X/NA	6,622	55.1% (53.8%; 56.4%)	40.3% (39.0%; 41.6%)	32.9% (31.6%; 34.2%)	29.4% (28.0%; 30.8%)	27.5% (26.1%; 29.1%)	26.8% (24.8%; 29.1%)	
Colon	All	27,105	84.8% (84.3%; 85.3%)	78.7% (78.1%; 79.3%)	75.2% (74.5%; 75.9%)	73.2% (72.4%; 74.0%)	72.1% (71.2%; 73.0%)	68.5% (65.5%; 71.5%)	
	I	5,921	98.8% (98.2%; 99.4%)	98.8% (98.0%; 99.5%)	98.6% (97.6%; 99.6%)	98.6% (97.3%; 99.9%)	98.1% (96.5%; 99.7%)	100.2% (95.5%; 105.1%)	
	II	8,092	95.5% (94.9%; 96.2%)	95.0% (94.1%; 95.9%)	94.3% (93.2%; 95.4%)	93.8% (92.5%; 95.2%)	93.6% (91.9%; 95.4%)	85.6% (79.9%; 91.8%)	
	III	7,386	88.0% (87.1%; 88.8%)	79.9% (78.8%; 81.0%)	74.9% (73.6%; 76.2%)	71.9% (70.5%; 73.4%)	70.6% (68.9%; 72.3%)	66.2% (59.0%; 74.4%)	
	IV	2,328	68.3% (66.3%; 70.3%)	49.2% (47.1%; 51.4%)	38.5% (36.4%; 40.8%)	31.7% (29.6%; 33.9%)	27.3% (25.2%; 29.6%)	20.0% (17.5%; 22.9%)	
	X/NA	3,777	43.9% (42.3%; 45.6%)	28.1% (26.6%; 29.8%)	20.7% (19.3%; 22.3%)	17.3% (15.8%; 18.9%)	15.8% (14.3%; 17.5%)	16.1% (14.0%; 18.5%)	
Rectum	All	8,600	87.3% (86.5%; 88.1%)	80.7% (79.7%; 81.7%)	75.9% (74.8%; 77.1%)	72.5% (71.3%; 73.8%)	70.5% (69.1%; 71.9%)	66.4% (63.4%; 69.5%)	
	I	2,423	99.7% (99.1%; 100.4%)	99.3% (98.3%; 100.4%)	98.8% (97.4%; 100.2%)	98.7% (97.0%; 100.5%)	98.9% (96.8%; 101.1%)	103.8% (97.5%; 110.5%)	
	II	1,337	96.6% (95.3%; 98.0%)	94.9% (93.1%; 96.8%)	92.4% (90.1%; 94.8%)	87.5% (84.6%; 90.5%)	85.4% (82.0%; 88.9%)	73.8% (65.6%; 82.9%)	
	III	1,629	94.1% (92.7%; 95.5%)	88.5% (86.6%; 90.5%)	81.4% (79.0%; 83.9%)	75.5% (72.7%; 78.4%)	71.0% (67.7%; 74.3%)	58.9% (52.4%; 66.2%)	
	IV	336	78.6% (74.1%; 83.3%)	63.1% (57.9%; 68.7%)	48.9% (43.5%; 55.0%)	39.2% (33.8%; 45.4%)	33.9% (28.5%; 40.2%)	20.8% (14.9%; 29.1%)	
	X/NA	2,878	69.7% (67.9%; 71.5%)	56.1% (54.1%; 58.2%)	48.8% (46.6%; 51.0%)	45.5% (43.2%; 47.9%)	43.2% (40.8%; 45.8%)	40.7% (37.0%; 44.7%)	

4.2.3. Colorectal cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2014-2023

Net Survival Probability, 2014-2023									
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total		79,318	86.2% (85.9%; 86.4%)	79.9% (79.6%; 80.3%)	75.8% (75.4%; 76.2%)	73.0% (72.5%; 73.4%)	71.3% (70.7%; 71.8%)	66.9% (65.2%; 68.6%)	
Males									
CRC	All	43,884	86.8% (86.4%; 87.1%)	80.5% (80.0%; 80.9%)	76.2% (75.6%; 76.7%)	72.9% (72.3%; 73.5%)	70.8% (70.1%; 71.5%)	66.0% (63.7%; 68.4%)	
	I	11,113	96.9% (96.4%; 97.4%)	96.3% (95.6%; 96.9%)	95.6% (94.8%; 96.5%)	94.9% (93.9%; 96.0%)	94.8% (93.5%; 96.0%)	96.2% (93.0%; 99.4%)	
	II	10,609	93.6% (93.0%; 94.3%)	91.9% (91.1%; 92.8%)	90.2% (89.2%; 91.3%)	88.3% (87.1%; 89.6%)	87.3% (85.8%; 88.8%)	76.8% (69.2%; 85.1%)	
	III	12,442	92.8% (92.2%; 93.4%)	87.5% (86.7%; 88.3%)	83.3% (82.4%; 84.3%)	79.5% (78.4%; 80.6%)	76.6% (75.3%; 77.9%)	72.5% (69.4%; 75.7%)	
	IV	8,920	62.6% (61.6%; 63.7%)	43.1% (42.0%; 44.2%)	30.9% (29.8%; 32.0%)	23.3% (22.3%; 24.4%)	18.9% (17.9%; 20.0%)	11.4% (10.0%; 13.0%)	
	X/NA	1,657	58.7% (56.1%; 61.3%)	48.3% (45.6%; 51.1%)	43.0% (40.2%; 46.0%)	39.2% (36.2%; 42.5%)	36.6% (33.4%; 40.0%)	31.1% (26.5%; 36.5%)	
Colon	All	30,495	86.0% (85.5%; 86.4%)	79.8% (79.2%; 80.4%)	75.8% (75.2%; 76.5%)	72.7% (72.0%; 73.5%)	70.9% (70.0%; 71.7%)	66.0% (62.9%; 69.2%)	
	I	7,798	97.0% (96.4%; 97.6%)	96.7% (95.9%; 97.5%)	96.1% (95.2%; 97.2%)	95.4% (94.2%; 96.7%)	95.3% (93.8%; 96.8%)	94.2% (90.5%; 98.0%)	
	II	8,434	94.5% (93.8%; 95.2%)	93.4% (92.5%; 94.3%)	92.2% (91.1%; 93.3%)	90.8% (89.4%; 92.2%)	90.1% (88.4%; 91.9%)	80.8% (71.4%; 91.5%)	
	III	7,236	91.3% (90.5%; 92.1%)	85.4% (84.4%; 86.5%)	80.8% (79.5%; 82.1%)	77.0% (75.5%; 78.6%)	73.8% (72.1%; 75.6%)	70.7% (66.3%; 75.4%)	
	IV	6,452	60.3% (59.1%; 61.6%)	40.9% (39.6%; 42.2%)	29.5% (28.2%; 30.7%)	22.2% (21.0%; 23.5%)	18.1% (16.9%; 19.3%)	11.0% (9.3%; 13.0%)	
	X/NA	1,081	57.5% (54.4%; 60.8%)	46.7% (43.4%; 50.2%)	42.2% (38.8%; 46.0%)	37.6% (34.0%; 41.5%)	35.2% (31.5%; 39.3%)	29.7% (23.9%; 36.8%)	
Rectum	All	13,963	88.4% (87.7%; 89.0%)	81.8% (81.0%; 82.6%)	76.7% (75.8%; 77.6%)	72.8% (71.7%; 73.9%)	70.3% (69.2%; 71.5%)	66.0% (63.5%; 68.6%)	
	I	3,400	96.4% (95.5%; 97.3%)	95.2% (94.0%; 96.4%)	94.3% (92.8%; 95.8%)	93.5% (91.7%; 95.4%)	93.1% (90.9%; 95.5%)	100.5% (94.5%; 106.9%)	
	II	2,213	90.4% (88.9%; 91.9%)	86.3% (84.4%; 88.3%)	82.7% (80.4%; 85.0%)	78.9% (76.3%; 81.7%)	76.6% (73.5%; 79.7%)	62.8% (55.5%; 71.0%)	
	III	5,260	94.8% (94.1%; 95.6%)	90.4% (89.3%; 91.5%)	86.7% (85.3%; 88.0%)	82.7% (81.1%; 84.4%)	80.2% (78.4%; 82.1%)	74.6% (70.8%; 78.6%)	
	IV	2,518	68.5% (66.7%; 70.5%)	48.9% (46.8%; 51.0%)	34.5% (32.5%; 36.6%)	26.1% (24.1%; 28.2%)	21.1% (19.2%; 23.2%)	12.7% (10.5%; 15.3%)	
	X/NA	581	60.8% (56.6%; 65.2%)	51.1% (46.6%; 55.9%)	44.1% (39.4%; 49.3%)	41.9% (36.7%; 47.7%)	38.8% (33.5%; 45.0%)	33.5% (27.3%; 41.2%)	
Females									
CRC	All	35,434	85.4% (85.0%; 85.8%)	79.2% (78.7%; 79.8%)	75.4% (74.8%; 76.0%)	73.1% (72.4%; 73.8%)	71.8% (71.0%; 72.6%)	68.1% (65.7%; 70.5%)	

Net Survival Probability, 2014-2023									
location	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	I	8,051	98.0% (97.5%; 98.6%)	97.5% (96.8%; 98.2%)	96.9% (96.0%; 97.8%)	96.6% (95.5%; 97.8%)	96.2% (94.8%; 97.6%)	98.1% (94.3%; 102.2%)	
	II	9,461	93.5% (92.9%; 94.2%)	92.4% (91.6%; 93.3%)	91.2% (90.2%; 92.3%)	90.3% (89.0%; 91.6%)	89.6% (88.1%; 91.3%)	81.6% (76.5%; 86.9%)	
	III	10,022	90.2% (89.5%; 90.9%)	84.7% (83.9%; 85.6%)	80.8% (79.8%; 81.9%)	78.0% (76.8%; 79.2%)	76.7% (75.3%; 78.1%)	73.4% (67.7%; 79.6%)	
	IV	7,010	58.7% (57.5%; 59.9%)	39.4% (38.3%; 40.7%)	28.9% (27.8%; 30.1%)	23.1% (22.0%; 24.3%)	19.6% (18.5%; 20.8%)	14.6% (13.1%; 16.1%)	
	X/NA	1,476	58.8% (56.1%; 61.6%)	45.8% (43.0%; 48.9%)	39.9% (37.0%; 43.1%)	37.6% (34.5%; 40.9%)	36.3% (33.1%; 39.8%)	33.5% (29.0%; 38.6%)	
Colon	All	27,105	84.8% (84.3%; 85.3%)	78.7% (78.1%; 79.3%)	75.2% (74.5%; 75.9%)	73.2% (72.4%; 74.0%)	72.1% (71.2%; 73.0%)	68.5% (65.5%; 71.5%)	
	I	6,100	98.0% (97.4%; 98.6%)	97.7% (96.9%; 98.5%)	97.2% (96.2%; 98.3%)	97.0% (95.7%; 98.3%)	96.4% (94.8%; 98.1%)	98.9% (94.4%; 103.7%)	
	II	8,088	94.0% (93.3%; 94.7%)	93.5% (92.6%; 94.4%)	92.8% (91.6%; 93.9%)	92.5% (91.1%; 93.8%)	92.2% (90.4%; 93.9%)	84.3% (78.6%; 90.4%)	
	III	6,721	88.6% (87.7%; 89.5%)	82.7% (81.6%; 83.8%)	78.9% (77.5%; 80.2%)	76.2% (74.7%; 77.8%)	75.3% (73.6%; 77.1%)	71.4% (63.5%; 80.2%)	
	IV	5,593	57.7% (56.4%; 59.0%)	38.2% (36.9%; 39.6%)	28.0% (26.7%; 29.3%)	22.6% (21.4%; 23.9%)	19.4% (18.2%; 20.7%)	15.1% (13.5%; 16.9%)	
	X/NA	1,008	56.4% (53.1%; 59.8%)	43.1% (39.8%; 46.8%)	37.5% (34.0%; 41.3%)	35.0% (31.3%; 39.0%)	34.1% (30.3%; 38.4%)	32.8% (27.8%; 38.7%)	
Rectum	All	8,600	87.3% (86.5%; 88.1%)	80.7% (79.7%; 81.7%)	75.9% (74.8%; 77.1%)	72.5% (71.3%; 73.8%)	70.5% (69.1%; 71.9%)	66.4% (63.4%; 69.5%)	
	I	1,982	98.2% (97.2%; 99.2%)	97.0% (95.6%; 98.4%)	95.8% (94.0%; 97.6%)	95.5% (93.3%; 97.7%)	95.4% (92.8%; 98.1%)	95.6% (88.8%; 103.0%)	
	II	1,389	90.7% (88.8%; 92.6%)	86.0% (83.6%; 88.5%)	82.3% (79.5%; 85.3%)	77.7% (74.4%; 81.2%)	75.2% (71.4%; 79.2%)	65.3% (57.3%; 74.5%)	
	III	3,327	93.4% (92.4%; 94.4%)	88.7% (87.4%; 90.1%)	84.6% (82.9%; 86.2%)	81.3% (79.5%; 83.2%)	79.3% (77.1%; 81.5%)	77.0% (72.2%; 82.1%)	
	IV	1,432	62.6% (60.1%; 65.3%)	44.2% (41.6%; 47.0%)	32.3% (29.8%; 35.1%)	25.1% (22.6%; 27.8%)	20.5% (18.1%; 23.1%)	12.8% (10.1%; 16.2%)	
	X/NA	474	63.7% (59.1%; 68.7%)	51.5% (46.5%; 57.1%)	44.8% (39.6%; 50.7%)	42.9% (37.4%; 49.3%)	40.7% (35.0%; 47.4%)	34.8% (26.7%; 45.4%)	

5. CANCER SURVIVAL TRENDS



5.1. Colorectal cancer survival trends: by tumour stage

5.1.1. Colorectal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	All	20,753	83.0% (82.4%; 83.5%)	69.2% (68.4%; 70.0%)	62.6% (61.6%; 63.5%)	17,504	82.1% (81.5%; 82.8%)	69.7% (68.9%; 70.5%)	64.4% (63.4%; 65.4%)
	I	3,162	95.5% (94.5%; 96.6%)	93.7% (92.1%; 95.3%)	90.8% (88.6%; 93.1%)	2,467	97.4% (96.4%; 98.4%)	97.0% (95.4%; 98.6%)	95.6% (93.3%; 97.9%)
	II	5,609	92.4% (91.5%; 93.3%)	87.0% (85.6%; 88.4%)	82.7% (80.9%; 84.6%)	5,047	91.7% (90.8%; 92.7%)	86.9% (85.5%; 88.3%)	83.5% (81.6%; 85.4%)
	III	5,651	87.4% (86.4%; 88.5%)	72.6% (71.1%; 74.1%)	63.5% (61.8%; 65.2%)	4,824	85.9% (84.8%; 87.0%)	71.3% (69.7%; 72.8%)	63.0% (61.2%; 64.9%)
	IV	3,644	63.1% (61.5%; 64.8%)	27.1% (25.6%; 28.7%)	15.7% (14.4%; 17.0%)	2,788	59.6% (57.7%; 61.5%)	24.8% (23.2%; 26.5%)	16.1% (14.6%; 17.6%)
	X/NA	2,970	67.4% (65.6%; 69.2%)	54.3% (52.2%; 56.5%)	50.0% (47.6%; 52.5%)	2,579	66.4% (64.5%; 68.4%)	55.9% (53.6%; 58.2%)	51.9% (49.4%; 54.6%)
2009-2013	All	22,749	84.8% (84.3%; 85.3%)	72.2% (71.5%; 72.9%)	66.1% (65.3%; 67.0%)	18,504	83.7% (83.1%; 84.3%)	71.6% (70.8%; 72.4%)	67.2% (66.3%; 68.2%)
	I	4,145	95.4% (94.5%; 96.3%)	92.9% (91.5%; 94.4%)	90.8% (88.9%; 92.8%)	3,208	96.6% (95.7%; 97.5%)	94.8% (93.3%; 96.3%)	92.9% (90.8%; 95.0%)
	II	5,997	93.2% (92.3%; 94.0%)	89.3% (88.0%; 90.6%)	85.7% (84.0%; 87.5%)	5,189	92.4% (91.5%; 93.4%)	88.4% (87.0%; 89.9%)	86.7% (84.8%; 88.6%)
	III	6,718	90.9% (90.1%; 91.8%)	79.0% (77.7%; 80.3%)	72.2% (70.7%; 73.8%)	5,386	89.3% (88.3%; 90.3%)	76.7% (75.3%; 78.2%)	71.5% (69.8%; 73.2%)
	IV	4,356	64.0% (62.5%; 65.5%)	30.7% (29.2%; 32.2%)	17.5% (16.2%; 18.9%)	3,324	59.4% (57.7%; 61.2%)	27.4% (25.8%; 29.0%)	17.4% (16.0%; 18.8%)
	X/NA	1,983	62.4% (60.1%; 64.7%)	44.5% (42.0%; 47.1%)	39.7% (37.0%; 42.5%)	1,694	62.7% (60.3%; 65.3%)	47.0% (44.3%; 49.9%)	42.2% (39.3%; 45.3%)
2014-2018	All	23,408	87.2% (86.7%; 87.7%)	77.4% (76.7%; 78.1%)	72.0% (71.1%; 72.8%)	18,493	85.4% (84.8%; 85.9%)	75.2% (74.4%; 76.0%)	71.7% (70.7%; 72.6%)
	I	6,038	97.3% (96.6%; 97.9%)	96.7% (95.7%; 97.8%)	95.7% (94.1%; 97.2%)	4,199	98.6% (97.9%; 99.2%)	97.5% (96.3%; 98.7%)	97.1% (95.4%; 98.8%)
	II	5,673	93.6% (92.8%; 94.5%)	90.6% (89.2%; 91.9%)	87.5% (85.6%; 89.4%)	4,914	93.0% (92.1%; 93.9%)	90.7% (89.3%; 92.2%)	89.2% (87.2%; 91.2%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	6,624	93.0% (92.2%; 93.8%)	84.6% (83.3%; 85.8%)	77.7% (76.1%; 79.3%)	5,250	90.1% (89.2%; 91.1%)	79.9% (78.5%; 81.3%)	75.7% (74.0%; 77.5%)
	IV	4,359	62.8% (61.3%; 64.3%)	30.6% (29.1%; 32.1%)	18.6% (17.4%; 20.0%)	3,392	58.7% (57.0%; 60.4%)	28.3% (26.7%; 29.9%)	18.7% (17.4%; 20.2%)
	X/NA	1,145	60.9% (57.9%; 64.0%)	44.7% (41.4%; 48.3%)	37.9% (34.3%; 41.9%)	1,012	58.2% (55.0%; 61.6%)	39.9% (36.4%; 43.6%)	36.9% (33.3%; 41.0%)
2019-2023	All	20,603	86.2% (85.7%; 86.8%)	74.5% (73.7%; 75.3%)	69.4% (68.2%; 70.6%)	17,050	85.4% (84.8%; 86.0%)	75.6% (74.8%; 76.5%)	71.8% (70.5%; 73.1%)
	I	5,094	96.4% (95.6%; 97.1%)	94.0% (92.7%; 95.4%)	94.0% (91.8%; 96.3%)	3,861	97.4% (96.6%; 98.2%)	96.1% (94.7%; 97.5%)	94.6% (92.2%; 97.1%)
	II	4,952	93.7% (92.7%; 94.6%)	89.8% (88.2%; 91.4%)	87.0% (84.4%; 89.8%)	4,559	94.1% (93.2%; 95.0%)	91.8% (90.2%; 93.4%)	90.0% (87.1%; 92.9%)
	III	5,831	92.5% (91.7%; 93.4%)	81.5% (80.1%; 83.0%)	75.2% (73.0%; 77.5%)	4,781	90.3% (89.3%; 91.3%)	81.9% (80.4%; 83.5%)	77.9% (75.6%; 80.3%)
	IV	4,561	62.5% (61.0%; 64.0%)	31.1% (29.6%; 32.7%)	19.3% (17.6%; 21.1%)	3,620	58.7% (57.0%; 60.4%)	29.8% (28.1%; 31.5%)	21.3% (19.5%; 23.2%)
	X/NA	512	53.6% (49.1%; 58.5%)	39.3% (34.4%; 45.0%)	34.4% (28.6%; 41.4%)	465	60.0% (55.2%; 65.1%)	39.6% (34.0%; 46.1%)	31.9% (25.2%; 40.5%)

5.2. Colorectal cancer survival trends: by sub-location and tumour stage

5.2.1. Colorectal cancer survival trends by sub-location, stage and sex: number at risk and net survival probabilities, 2004-2023

Period	sub-location	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	Colon	All	14,221	81.6% (80.9%; 82.4%)	68.3% (67.4%; 69.3%)	62.1% (61.0%; 63.2%)	12,971	81.2% (80.4%; 81.9%)	69.1% (68.2%; 70.1%)	64.6% (63.5%; 65.8%)
		I	1,993	94.9% (93.6%; 96.3%)	93.0% (91.0%; 95.2%)	90.5% (87.7%; 93.5%)	1,628	97.3% (96.1%; 98.6%)	97.2% (95.2%; 99.3%)	96.0% (93.1%; 98.9%)
		II	4,115	92.8% (91.8%; 93.9%)	88.1% (86.5%; 89.7%)	84.8% (82.7%; 87.0%)	4,067	91.7% (90.6%; 92.8%)	88.1% (86.6%; 89.7%)	85.8% (83.7%; 87.9%)
		III	3,558	85.0% (83.7%; 86.4%)	69.8% (67.9%; 71.7%)	60.6% (58.4%; 62.8%)	3,353	84.0% (82.6%; 85.4%)	69.4% (67.5%; 71.3%)	62.2% (60.0%; 64.5%)
		IV	2,650	60.4% (58.5%; 62.4%)	26.3% (24.5%; 28.1%)	14.9% (13.4%; 16.5%)	2,169	57.4% (55.3%; 59.6%)	23.3% (21.5%; 25.3%)	15.5% (13.9%; 17.3%)
		X/NA	2,077	67.7% (65.5%; 69.9%)	56.5% (54.0%; 59.1%)	52.8% (49.9%; 55.8%)	1,901	67.2% (64.9%; 69.5%)	56.8% (54.2%; 59.6%)	53.2% (50.2%; 56.3%)
	Rectum	All	6,694	85.8% (84.9%; 86.8%)	70.9% (69.6%; 72.2%)	63.4% (61.8%; 64.9%)	4,618	84.9% (83.7%; 86.0%)	71.2% (69.6%; 72.7%)	63.5% (61.7%; 65.4%)
		I	1,185	96.6% (95.1%; 98.2%)	94.9% (92.4%; 97.4%)	91.4% (88.0%; 95.0%)	849	97.1% (95.4%; 98.8%)	96.4% (93.8%; 99.1%)	94.7% (90.8%; 98.7%)
		II	1,502	91.4% (89.7%; 93.2%)	84.0% (81.4%; 86.7%)	76.9% (73.7%; 80.3%)	990	92.1% (90.1%; 94.2%)	81.6% (78.4%; 84.9%)	74.1% (70.1%; 78.2%)
		III	2,107	91.5% (90.0%; 92.9%)	77.1% (74.9%; 79.5%)	68.2% (65.5%; 71.0%)	1,477	90.2% (88.4%; 91.9%)	75.4% (72.8%; 78.1%)	64.7% (61.7%; 67.9%)
		IV	1,000	70.1% (67.1%; 73.1%)	29.1% (26.3%; 32.3%)	17.6% (15.2%; 20.5%)	621	67.1% (63.4%; 71.1%)	29.9% (26.4%; 34.0%)	17.9% (14.9%; 21.6%)
		X/NA	901	66.5% (63.2%; 69.9%)	49.1% (45.4%; 53.2%)	43.2% (39.3%; 47.6%)	681	63.9% (60.2%; 67.9%)	52.9% (48.7%; 57.5%)	48.1% (43.5%; 53.2%)
2009-2013	Colon	All	15,613	83.7% (83.0%; 84.4%)	71.2% (70.3%; 72.1%)	65.7% (64.7%; 66.8%)	13,902	83.2% (82.5%; 83.9%)	71.2% (70.3%; 72.2%)	67.4% (66.3%; 68.6%)
		I	2,808	95.3% (94.2%; 96.4%)	93.7% (92.0%; 95.5%)	92.0% (89.6%; 94.4%)	2,309	96.5% (95.4%; 97.6%)	94.8% (93.1%; 96.6%)	92.6% (90.2%; 95.1%)
		II	4,627	93.7% (92.7%; 94.6%)	90.7% (89.2%; 92.2%)	88.0% (86.0%; 90.1%)	4,332	93.1% (92.1%; 94.1%)	89.9% (88.4%; 91.5%)	89.0% (86.9%; 91.2%)
		III	3,879	89.1% (87.9%; 90.3%)	75.9% (74.1%; 77.6%)	69.2% (67.1%; 71.4%)	3,710	87.3% (86.1%; 88.6%)	73.9% (72.1%; 75.7%)	69.2% (67.1%; 71.3%)
		IV	3,150	62.3% (60.5%; 64.1%)	28.9% (27.2%; 30.7%)	16.7% (15.2%; 18.4%)	2,555	58.1% (56.1%; 60.1%)	25.8% (24.0%; 27.6%)	16.8% (15.3%; 18.4%)
		X/NA	1,421	60.8% (58.1%; 63.6%)	43.5% (40.5%; 46.6%)	38.6% (35.4%; 42.0%)	1,217	63.0% (60.2%; 66.0%)	47.5% (44.3%; 51.0%)	42.5% (39.1%; 46.3%)
	Rectum	All	7,389	87.2% (86.3%; 88.1%)	74.2% (73.0%; 75.5%)	66.8% (65.3%; 68.2%)	4,716	85.3% (84.2%; 86.4%)	72.7% (71.2%; 74.3%)	66.5% (64.7%; 68.3%)

Period	sub-location	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	1,361	95.5% (93.9%; 97.0%)	91.3% (88.8%; 93.8%)	88.0% (84.8%; 91.3%)	907	96.9% (95.3%; 98.6%)	94.9% (92.2%; 97.8%)	93.7% (89.9%; 97.6%)
		II	1,384	91.7% (89.9%; 93.5%)	84.6% (81.9%; 87.4%)	77.9% (74.5%; 81.5%)	861	89.2% (86.8%; 91.7%)	81.0% (77.7%; 84.5%)	74.8% (70.8%; 79.1%)
		III	2,863	93.4% (92.3%; 94.6%)	83.3% (81.5%; 85.1%)	76.2% (74.0%; 78.5%)	1,688	93.6% (92.2%; 95.0%)	83.0% (80.7%; 85.3%)	76.6% (73.8%; 79.4%)
		IV	1,215	68.4% (65.7%; 71.2%)	35.0% (32.2%; 38.0%)	19.5% (17.2%; 22.1%)	778	63.9% (60.4%; 67.5%)	32.5% (29.2%; 36.1%)	19.3% (16.6%; 22.6%)
		X/NA	569	65.6% (61.5%; 70.0%)	46.4% (41.8%; 51.4%)	41.9% (37.0%; 47.4%)	486	62.0% (57.5%; 66.8%)	45.2% (40.4%; 50.6%)	41.1% (36.1%; 46.7%)
2014-2018	Colon	All	16,235	86.4% (85.8%; 87.0%)	76.9% (76.0%; 77.7%)	72.0% (70.9%; 73.1%)	14,151	84.6% (83.9%; 85.2%)	74.8% (73.9%; 75.7%)	71.9% (70.8%; 73.0%)
		I	4,266	97.5% (96.7%; 98.3%)	97.2% (95.9%; 98.4%)	96.3% (94.5%; 98.1%)	3,161	98.5% (97.7%; 99.3%)	97.6% (96.3%; 99.0%)	97.3% (95.3%; 99.3%)
		II	4,471	94.3% (93.4%; 95.3%)	92.4% (90.9%; 93.9%)	90.4% (88.3%; 92.6%)	4,201	93.3% (92.3%; 94.3%)	91.9% (90.4%; 93.5%)	91.4% (89.3%; 93.6%)
		III	3,853	91.5% (90.5%; 92.6%)	82.3% (80.6%; 84.0%)	75.4% (73.3%; 77.6%)	3,557	88.8% (87.6%; 90.1%)	78.1% (76.3%; 79.9%)	74.5% (72.3%; 76.8%)
		IV	3,143	60.3% (58.5%; 62.1%)	28.6% (26.9%; 30.3%)	17.3% (15.8%; 18.9%)	2,724	56.7% (54.8%; 58.6%)	27.0% (25.3%; 28.8%)	18.3% (16.7%; 19.9%)
		X/NA	768	60.0% (56.3%; 63.8%)	43.7% (39.7%; 48.2%)	36.4% (32.1%; 41.3%)	699	56.5% (52.7%; 60.6%)	37.7% (33.6%; 42.2%)	35.0% (30.8%; 39.9%)
	Rectum	All	7,455	88.8% (87.9%; 89.6%)	78.2% (77.0%; 79.4%)	71.4% (69.9%; 72.9%)	4,470	87.9% (86.8%; 89.0%)	76.3% (74.8%; 77.9%)	70.8% (69.0%; 72.6%)
		I	1,819	96.6% (95.4%; 97.8%)	95.5% (93.6%; 97.5%)	93.6% (90.7%; 96.5%)	1,051	98.8% (97.6%; 100.1%)	97.1% (94.8%; 99.5%)	96.8% (93.6%; 100.2%)
		II	1,217	90.9% (89.0%; 92.9%)	83.7% (80.8%; 86.7%)	76.6% (72.9%; 80.5%)	717	91.6% (89.1%; 94.1%)	84.0% (80.3%; 87.8%)	76.0% (71.3%; 81.0%)
		III	2,794	95.1% (94.1%; 96.2%)	87.8% (86.1%; 89.6%)	80.9% (78.6%; 83.3%)	1,708	92.8% (91.3%; 94.2%)	83.3% (81.1%; 85.6%)	78.0% (75.3%; 80.9%)
		IV	1,246	68.9% (66.2%; 71.6%)	35.6% (32.8%; 38.6%)	22.0% (19.6%; 24.8%)	677	67.3% (63.7%; 71.1%)	33.3% (29.7%; 37.3%)	20.7% (17.7%; 24.2%)
		X/NA	381	63.0% (58.0%; 68.5%)	46.3% (40.7%; 52.7%)	40.5% (34.3%; 47.9%)	318	61.6% (56.0%; 67.7%)	44.4% (38.4%; 51.3%)	40.8% (34.3%; 48.5%)
2019-2023	Colon	All	14,331	85.5% (84.9%; 86.2%)	74.4% (73.4%; 75.4%)	69.2% (67.7%; 70.7%)	13,028	85.0% (84.3%; 85.7%)	75.6% (74.6%; 76.6%)	72.1% (70.6%; 73.7%)
		I	3,545	96.5% (95.5%; 97.4%)	94.7% (93.0%; 96.3%)	94.3% (91.6%; 97.0%)	2,945	97.4% (96.5%; 98.3%)	96.7% (95.1%; 98.4%)	95.0% (92.2%; 98.0%)
		II	3,974	94.7% (93.7%; 95.7%)	91.9% (90.2%; 93.7%)	89.4% (86.3%; 92.5%)	3,896	94.8% (93.9%; 95.8%)	93.7% (92.0%; 95.4%)	92.4% (89.3%; 95.7%)
		III	3,388	91.0% (89.8%; 92.2%)	78.8% (76.8%; 80.8%)	71.3% (68.2%; 74.5%)	3,170	88.4% (87.0%; 89.7%)	79.9% (77.9%; 81.9%)	76.8% (73.9%; 79.7%)
		IV	3,309	60.3% (58.6%; 62.1%)	30.4% (28.6%; 32.3%)	19.2% (17.2%; 21.4%)	2,871	58.7% (56.8%; 60.6%)	29.1% (27.3%; 31.1%)	21.2% (19.2%; 23.4%)
		X/NA	313	51.6% (45.9%; 58.0%)	39.1% (33.0%; 46.3%)	33.0% (26.1%; 41.7%)	310	55.8% (50.1%; 62.2%)	37.1% (30.7%; 44.8%)	28.7% (20.8%; 39.7%)

Period	sub-location	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	Rectum	All	6,510	87.9% (87.0%; 88.8%)	74.6% (73.2%; 76.0%)	69.7% (67.7%; 71.7%)	4,130	86.6% (85.5%; 87.8%)	75.4% (73.7%; 77.2%)	70.0% (67.7%; 72.5%)
		I	1,581	96.2% (94.8%; 97.5%)	92.5% (90.1%; 95.0%)	93.4% (89.7%; 97.2%)	931	97.5% (96.0%; 99.0%)	94.0% (91.2%; 96.9%)	92.9% (88.4%; 97.6%)
		II	996	89.8% (87.5%; 92.2%)	81.1% (77.5%; 85.0%)	77.8% (72.5%; 83.4%)	672	89.7% (87.0%; 92.6%)	80.3% (75.9%; 84.9%)	75.5% (69.5%; 82.1%)
		III	2,466	94.5% (93.4%; 95.7%)	85.1% (83.0%; 87.2%)	80.5% (77.6%; 83.6%)	1,619	94.1% (92.7%; 95.5%)	85.8% (83.4%; 88.2%)	79.9% (76.1%; 83.8%)
		IV	1,272	68.2% (65.6%; 71.0%)	33.2% (30.3%; 36.3%)	19.9% (17.0%; 23.3%)	755	58.4% (54.9%; 62.2%)	32.1% (28.6%; 36.1%)	21.4% (17.7%; 26.0%)
		X/NA	200	56.5% (49.6%; 64.4%)	39.8% (32.0%; 49.4%)	36.7% (27.4%; 49.1%)	156	68.2% (60.4%; 76.9%)	44.7% (34.9%; 57.2%)	38.3% (27.5%; 53.3%)

6. CANCER MORTALITY



6.1. Colorectal cancer mortality: by region

6.1.1. Colorectal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Males																						
Belgium	0	0	0	0	1	0	5	3	10	16	45	72	109	134	199	175	211	204	114	25	1,323	26.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[1.3]	[0.8]	[2.7]	[4.2]	[11.3]	[17.8]	[30.0]	[43.7]	[75.1]	[100.5]	[161.5]	[262.6]	[406.1]	[458.4]	[23.3]	(25.2; 28.2)
Brussels	0	0	0	0	0	0	0	1	0	2	5	4	7	14	18	18	11	22	8	0	110	31.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[0.0]	[4.6]	[12.5]	[11.7]	[25.6]	[67.4]	[107.8]	[156.6]	[130.1]	[435.3]	[367.8]	[0.0]	[18.4]	(25.7; 37.8)
Flanders	0	0	0	0	1	0	4	1	5	12	23	45	53	70	102	92	126	112	79	17	742	23.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[1.9]	[0.5]	[2.3]	[5.6]	[9.8]	[18.4]	[24.0]	[37.3]	[63.0]	[80.6]	[146.1]	[216.6]	[431.2]	[474.7]	[22.5]	(22.1; 25.5)
Wallonia	0	0	0	0	0	0	1	1	5	2	17	23	49	50	79	65	74	70	27	8	471	32.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.9]	[4.3]	[1.6]	[13.7]	[18.4]	[42.7]	[51.1]	[91.4]	[133.9]	[205.9]	[334.3]	[356.3]	[569.0]	[26.4]	(29.1; 35.1)
Females																						
Belgium	0	1	0	0	0	1	7	6	7	16	18	46	62	91	115	120	191	224	133	58	1,096	15.8
	[0.0]	[0.3]	[0.0]	[0.0]	[0.0]	[0.3]	[1.9]	[1.6]	[1.9]	[4.3]	[4.6]	[11.5]	[16.7]	[27.9]	[38.8]	[56.3]	[103.2]	[165.7]	[200.7]	[301.6]	[18.8]	(14.8; 16.7)
Brussels	0	1	0	0	0	0	1	0	0	1	2	5	5	2	10	7	24	19	5	2	84	15.4
	[0.0]	[2.6]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[0.0]	[0.0]	[2.5]	[5.4]	[14.9]	[16.8]	[8.2]	[46.4]	[43.1]	[175.2]	[187.0]	[87.1]	[102.2]	[13.5]	(12.0; 18.7)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Flanders	0	0	0	0	0	1	4	2	3	9	7	22	30	45	64	74	93	143	83	39	619	14.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.9]	[1.0]	[1.4]	[4.3]	[3.1]	[9.2]	[13.6]	[23.3]	[36.8]	[55.5]	[80.1]	[168.2]	[207.0]	[347.3]	[18.4]	(13.3; 15.6)
Wallonia	0	0	0	0	0	0	2	4	4	6	9	19	27	44	41	39	74	62	45	17	393	18.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[3.5]	[3.5]	[4.9]	[7.3]	[14.9]	[22.3]	[40.5]	[40.7]	[61.2]	[134.1]	[154.8]	[220.4]	[281.4]	[21.1]	(16.6; 20.3)

7. CANCER MORTALITY TRENDS



7.1. Colorectal cancer mortality trends: by region

7.1.1. Colorectal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	1,459	1,535	1,501	1,540	1,577	1,546	1,580	1,546	1,572	1,494	1,442	1,530	1,482	1,514	1,348	1,348	1,321	1,323		
	CR	28.7	30.0	29.2	29.7	30.2	29.3	29.7	28.8	29.0	27.4	26.3	27.8	26.8	27.2	24.1	24.0	23.3	23.3		
	ESR2013	41.6	44.5	41.9	40.5	41.3	39.7	39.4	37.7	37.6	35.9	33.1	34.3	32.7	32.3	28.3	28.0	26.9	26.7	-2.9 (-3.2; -2.6)	2004-2021
																				-1.8 (-2.4; -1.1)	2004-2012
																				-3.9 (-4.5; -3.4)	2013-2021
Brussels	N	114	129	118	130	107	138	123	127	120	109	106	109	116	132	114	109	103	110		
	CR	23.7	26.7	24.1	26.2	21.2	26.7	23.3	23.4	21.7	19.4	18.7	19.0	20.0	22.7	19.4	18.4	17.2	18.4		
	ESR2013	39.3	43.6	39.3	42.0	32.7	43.2	39.4	38.4	37.2	33.3	31.6	33.2	32.6	38.1	32.3	32.0	27.5	31.7	-1.9 (-2.7; -1.1)	2004-2021
Flanders	N	928	948	957	928	915	973	983	958	984	908	858	968	884	881	798	780	760	742		
	CR	31.3	31.8	31.9	30.8	30.1	31.8	31.9	30.8	31.4	28.8	27.1	30.4	27.6	27.3	24.6	23.9	23.2	22.5		
	ESR2013	43.6	44.8	43.7	40.0	39.9	40.3	39.7	38.0	38.1	35.2	31.9	34.7	31.2	29.9	26.8	25.6	24.5	23.8	-3.7 (-4.0; -3.3)	2004-2021
																				-2.0 (-2.8; -1.3)	2004-2012
																				-5.1 (-5.7; -4.4)	2013-2021
Wallonia	N	417	458	426	482	555	435	474	461	468	477	478	453	482	501	436	459	458	471		
	CR	25.4	27.8	25.7	28.9	33.1	25.8	27.9	26.9	27.1	27.5	27.4	25.9	27.4	28.4	24.6	25.8	25.7	26.4		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
ESR2013	37.8	44.1	39.0	40.5	46.7	37.3	38.6	37.3	36.5	38.5	36.1	33.8	35.6	36.0	30.5	32.0	31.6	32.1	-1.7 (-2.3; -1.1)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Colorectal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	1,394	1,398	1,417	1,416	1,397	1,494	1,348	1,385	1,401	1,372	1,315	1,278	1,272	1,313	1,244	1,278	1,199	1,096		
	CR	26.3	26.2	26.4	26.2	25.7	27.2	24.4	24.8	24.9	24.3	23.2	22.4	22.2	22.8	21.5	22.0	20.6	18.8		
	ESR2013	26.2	26.0	25.6	25.2	24.4	25.9	22.5	22.9	22.8	22.0	20.8	19.9	19.6	19.9	18.6	18.8	17.2	15.8	-2.7 (-3.0; -2.4)	2004-2021
																				-1.9 (-2.7; -1.2)	2004-2012
																				-3.4 (-4.1; -2.7)	2013-2021
Brussels	N	139	134	151	117	130	138	124	123	121	113	118	123	90	113	116	116	98	84		
	CR	26.8	25.6	28.5	21.9	24.0	25.0	22.0	21.3	20.6	19.1	19.8	20.4	14.8	18.5	19.0	18.8	15.8	13.5		
	ESR2013	25.6	25.2	27.9	21.5	24.7	26.2	22.1	22.1	21.4	20.1	20.3	22.4	16.4	20.0	21.5	21.2	17.5	15.4	-2.4 (-3.3; -1.5)	2004-2021
Flanders	N	792	810	823	820	807	855	789	796	816	775	748	702	738	736	688	709	644	619		
	CR	26.0	26.4	26.7	26.4	25.9	27.2	24.9	24.9	25.4	24.0	23.1	21.5	22.5	22.3	20.8	21.3	19.2	18.4		
	ESR2013	26.1	26.5	25.9	25.4	24.4	25.4	22.6	22.6	22.7	21.2	20.1	18.5	19.0	18.6	17.1	17.3	15.2	14.5	-3.3 (-3.7; -3.0)	2004-2021
																				-2.1 (-2.9; -1.2)	2004-2011
																				-4.2 (-4.8; -3.7)	2012-2021
Wallonia	N	463	454	443	479	460	501	435	466	464	484	449	453	444	464	440	453	457	393		
	CR	26.6	26.0	25.2	27.1	25.9	28.0	24.2	25.7	25.5	26.5	24.5	24.6	24.1	25.1	23.7	24.4	24.5	21.1		
	ESR2013	26.5	25.5	24.6	25.9	24.5	26.7	22.4	23.6	23.6	23.9	22.1	21.8	21.7	22.2	20.8	21.3	21.1	18.5	-1.6 (-2.0; -1.2)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025